HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and raised the price target from $50 to $65.
June 07, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Halozyme Therapeutics and raised the price target from $50 to $65.
The raised price target and maintained Buy rating from a reputable analyst firm like HC Wainwright & Co. is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100